Overall, the combination of CD19 (+) B cells and PNI comprehensively assessed the patient’s status from the perspective of immunity, nutrition, and inflammation, and could accurately predict the clinical outcome of gastric cancer patients. This evidence concerns the gene CD19 and gastric cancer.